Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effect the postoperative combination of
therapies: trastuzumab (herceptin) and paclitaxel (taxol) will have on breast cancer
recurrence. A combination of trastuzuamb and chemotherapy has been used in women with node
positive and high risk node negative disease. This tests utilizes a well tolerated regimen of
weekly paclitaxel and trastuzumab in women with T1, node negative tumors that are HER2
positive. We would like to determine how effective this drug combination is when used in
women with early stage breast cancer, as well as to better define the side effects of this
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Eric P Winer, MD Eric Winer, MD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital